Barts Health NHS Trust

Study published in JAHA validates use of proprietary technology to identify personalized dose regimen, leading to improved blood pressure control and exceptionally high adherence in hypertension patients Findings will guide the Company’s strategy to expand portfolio of differentiated dose-optimized therapies, including within GLP-1 market LONDON--(BUSINESS WIRE)-- Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, today announced the publication of a peer-reviewed study in the Journal of the American Heart Association (JAHA) (1). The study describes results of the PERSONAL-CovidBP clinical trial; demonstrating the capabilities of the Company’s integrated precision care solution, CLM-HT01, to successfully control blood pressure (BP) whilst minimizing side effects and supporting medication adherence in participants with primary hypertension. The findings will be applied to drive further development of CLM-HT01 and the Company’s extended pipeline of combination products in other therapeutic areas, aiming to deliver precision dosing at population scale. Hypertension is the leading preventable cause of morbidity and premature death worldwide. Despite being a first-line recommended anti-hypertensive drug, ~20% of patients discontinue amlodipine after a single prescription largely due to unwanted effects, such as peripheral oedema, which is strongly dependent on dose. CLM-HT01 is a single label combination product in development, linking Closed Loop Medicine’s proprietary software as a medical device (SaMD) with amlodipine, designed to support more effective, precise, and affordable disease management solutions to improve outcomes for patients and streamline clinician input. The study “Personalized antihypertensive treatment optimization with smartphone-enabled remote precision dosing of amlodipine during the COVID-19 pandemic” reinforces the ability to use a digital companion alongside traditional therapeutics to optimize clinical outcomes. This was achieved by adjusting and personalizing drug dosing using information recorded by participants into a dedicated smartphone app and transmitted securely to a clinician. Clinically significant reductions in BP were rapidly observed, with the majority of participants achieving BP control and minimizing side effects, including those previously intolerant of conventional amlodipine doses. High adherence rates were reported (both app usage and medication) and patient retention was exceptionally high with no discontinuations due to drug intolerance. The findings build on preliminary results published in the Journal of the American College of Cardiology (2) and the Journal of Human Hypertension (3). Dr. Hakim Yadi OBE, CEO & Co-Founder of Closed Loop Medicine, commented: “These findings are invaluable in demonstrating the power of personalizing the dose of existing therapeutics in areas as widely impactful as hypertension. We now want to take these learnings and apply them more broadly where we feel they will have the most impact, for example to minimize the adverse effects limiting GLP-1 programmes – an area currently seeing huge attention.” He added: “To improve patient outcomes, we need to shift to a world where we treat the individual, not just the disease. Our inventions will work in combination with medicine to deliver personalized, optimized dosing; improving human health.” Dr. David Collier, the lead trial investigator from Queen Mary University of London, said: “We are incredibly pleased to have the final results from the PERSONAL-CovidBP trial published in the JAHA, a leading open access scientific journal.” He added: “We wanted to use personalized dosing of amlodipine, and had worked with our patients to develop a digital platform to allow this. Working remotely due to COVID we still managed to recruit, triage (selected participants according to home blood pressure), and then treat patients with this novel approach. Often starting with very small doses, empowering participants to share both wanted and unwanted effects of medication helped us to work together to reduce blood pressure while minimizing any side-effects. Some participants who had never tolerated full doses of any blood pressure medication got control for the first time.” Dr. Mike Taylor, Senior Vice President Clinical Development of Closed Loop Medicine, added: “Data generated in this study in hypertension demonstrate significant benefits offered by precision dose titration enabled by a dedicated smart phone app. This novel technology enables clinicians to efficiently personalize and optimize therapy routines for patients, leading to improved health outcomes by finding a better balance between efficacy and unwanted effects. Daily self-monitoring and side effect reporting empowers patients through a more comprehensive understanding of how medication impacts overall wellbeing, whilst providing more peace of mind knowing that a clinician is able to assess changes in real-time and optimize the tolerability and efficacy of said drug treatment.” PERSONAL-CovidBP was part-funded by Innovate UK and run by the William Harvey Clinical Research Centre at Queen Mary University of London, part of the National Institute for Health Research Biomedical Research Centre at Barts NHS Trust in London. Collier D et al. 2024. Taylor M et al. 2022. (22)02988-6 Collier D et al. 2022. View source version on businesswire.com: Contacts Lily Jeffery lily.jeffery@zymecommunications.com Source: Closed Loop Medicine View this news release online at:

OWKIN and International Partners Discuss First Learnings of Revolutionary Spatial Omics Initiative with Biopharma and IT Leaders LONDON, Oct. 12, 2023 /PRNewswire/ -- A Plenary Keynote address on the first learnings of the $50 million MOSAIC initiative, whose goal is to revolutionize cancer research through spatial omics technologies, will kick off Bio-IT World Conference & Expo Europe, taking place 29-30 November in London. This annual gathering fosters collaboration among the United Kingdom's and Europe's medical research, biopharma and technology leaders, who are forging new frontiers in precision medicine together. Continue Reading Bio-IT World Conference & Expo Europe In June, OWKIN and world-leading cancer research institutions and technology companies from France, Germany, Switzerland and the United States unveiled MOSAIC, which uses spatial omics to uncover unprecedented information on tumor structures at near single-cell resolution, and map the location and molecular activity of tumor and immune cells. The project is also a milestone for its scale—examining 7,000 tumor samples—100 times larger than other datasets. Spatial omics, combined with AI/ML, will help the partners advance novel therapies for seven difficult-to-treat cancers. "MOSAIC represents the innovations in precision medicine that are only possible when scientific and technology experts collaborate," said Cindy Crowninshield, RDN, LDN, Executive Event Director. "These partners will inspire and catalyze new discussions within the bio-IT community." Presenters include: Dr. Barbara Domayne-Hayman, Entrepreneur-in-Residence, Francis Crick Institute Markus Eckstein, M.D., Senior Consultant in Surgical Pathology, Institute of Pathology of FAU Medical School and University Hospital Erlangen/UKER Raphael Gottardo, Ph.D., Professor and Director, Biomedical Data Science Center, Lausanne University Hospital and University of Lausanne Joseph Lehár, Ph.D., Senior Vice President Business Strategy, OWKIN Another Bio-IT World Europe Plenary Keynote will focus on an AI-driven partnership between Barts Health NHS Trust and Queen Mary University of London. For more on the 60+ conference sessions and discounts (until 20 October), see bio-itworldeurope.com. About Bio-IT World Conference & Expo For over 20 years, Cambridge Healthtech Institute's Bio-IT World Conference & Expo has been the world's premier event showcasing technologies and analytic approaches that solve problems, accelerate science, and drive the future of precision medicine. Bio-IT World unites a community of leading life sciences, pharmaceutical, clinical, healthcare, informatics and technology experts in the field of biomedical research, drug discovery & development, and healthcare from around the world. SOURCE Cambridge Healthtech Institute

LONDON, Oct. 12, 2023 -- A Plenary Keynote address on the first learnings of the $50 million MOSAIC initiative, whose goal is to revolutionize cancer research through spatial omics technologies, will kick off Bio-IT World Conference & Expo Europe, taking place 29-30 November in London. This annual gathering fosters collaboration among the United Kingdom's and Europe's medical research, biopharma and technology leaders, who are forging new frontiers in precision medicine together. In June, OWKIN and world-leading cancer research institutions and technology companies from France, Germany, Switzerland and the United States unveiled MOSAIC, which uses spatial omics to uncover unprecedented information on tumor structures at near single-cell resolution, and map the location and molecular activity of tumor and immune cells. The project is also a milestone for its scale—examining 7,000 tumor samples—100 times larger than other datasets. Spatial omics, combined with AI/ML, will help the partners advance novel therapies for seven difficult-to-treat cancers. "MOSAIC represents the innovations in precision medicine that are only possible when scientific and technology experts collaborate," said Cindy Crowninshield, RDN, LDN, Executive Event Director. "These partners will inspire and catalyze new discussions within the bio-IT community." Presenters include: · Dr. Barbara Domayne-Hayman, Entrepreneur-in-Residence, Francis Crick Institute · Markus Eckstein, M.D., Senior Consultant in Surgical Pathology, Institute of Pathology of FAU Medical School and University Hospital Erlangen/UKER · Raphael Gottardo, Ph.D., Professor and Director, Biomedical Data Science Center, Lausanne University Hospital and University of Lausanne · Joseph Lehár, Ph.D., Senior Vice President Business Strategy, OWKIN Another Bio-IT World Europe Plenary Keynote will focus on an AI-driven partnership between Barts Health NHS Trust and Queen Mary University of London. For more on the 60+ conference sessions and discounts (until 20 October), see bio-itworldeurope.com. About Bio-IT World Conference & Expo For over 20 years, Cambridge Healthtech Institute's Bio-IT World Conference & Expo has been the world's premier event showcasing technologies and analytic approaches that solve problems, accelerate science, and drive the future of precision medicine. Bio-IT World unites a community of leading life sciences, pharmaceutical, clinical, healthcare, informatics and technology experts in the field of biomedical research, drug discovery & development, and healthcare from around the world.